Clinical Trials Logo

Filter by:
NCT ID: NCT03625882 Completed - Gaucher Disease Clinical Trials

Survey Study for Velaglucerase Alfa (VPRIV) in Japan

Start date: September 12, 2014
Phase:
Study type: Observational

The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.

NCT ID: NCT03624127 Completed - Psoriasis Clinical Trials

Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

POETYK-PSO-1
Start date: August 7, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

NCT ID: NCT03622580 Completed - Clinical trials for Diabetic Macular Edema

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

Start date: September 5, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

NCT ID: NCT03622112 Completed - Asthma Clinical Trials

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Start date: January 2, 2019
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy and safety of multiple dose levels of AZD7594 administered once daily (QD) by inhalation in a 12-week treatment period on asthma subjects. The activity will be assessed by comparing AZD7594 to placebo. The comparison between active comparator (FF) and placebo will be used for bench marking. The efficacy is assessed by the evaluation of change in trough forced expiratory volume in 1 second (FEV1). The aim is to develop AZD7594 as a once daily inhaled non-steroidal selective GR modulator (SGRM), which may ultimately lead to better disease control of both chronic obstructive pulmonary disease (COPD) and asthma through improved efficacy and compliance. The overall rationale for developing a once daily AZD7594 in a dry powder inhaler (DPI) is to provide a safe and effective future treatment option for both asthma and COPD subjects.

NCT ID: NCT03620981 Completed - Clinical trials for Agitation Associated With Dementia of the Alzheimer's Type

Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Start date: August 20, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the superiority of brexpiprazole 1 mg or 2 mg over placebo after a 10-week treatment regimen for agitation associated with dementia of the Alzheimer's type in patients who require medication, and to investigate the safety of brexpiprazole and identify the optimum dose.

NCT ID: NCT03620747 Completed - Asthma Clinical Trials

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

Start date: August 30, 2018
Phase: Phase 3
Study type: Interventional

Primary Objective: To describe the long-term safety of dupilumab in treatment of participants with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).

NCT ID: NCT03620474 Completed - Hepatitis C Clinical Trials

Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis

Start date: July 24, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

To investigate the safety and efficacy of PRI-724 against HCV or HBV liver cirrhosis.

NCT ID: NCT03619213 Completed - Clinical trials for Heart Failure With Preserved Ejection Fraction

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

DELIVER
Start date: August 27, 2018
Phase: Phase 3
Study type: Interventional

This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.

NCT ID: NCT03616964 Completed - Clinical trials for Systemic Lupus Erythematosus

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)

BRAVE II
Start date: August 2, 2018
Phase: Phase 3
Study type: Interventional

The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

NCT ID: NCT03612557 Completed - Healthy Clinical Trials

A Study of Benzathine Benzylpenicillin Intramuscular Injection in Japanese Healthy Subjects

Start date: August 20, 2018
Phase: Phase 1
Study type: Interventional

This will be an open label study to investigate the pharmacokinetics (PK) and safety of a single intramuscular injection of penicillin G benzathine in Japanese healthy subjects.